Lp(a) affects one in five adults worldwide yet has had no targeted therapy for sixty years. In 2026, four Phase 3 trials including HORIZON, OCEAN(a)-Outcomes, ACCLAIM-Lp(a), and a new oral…
Insilico Medicine has formed the industry’s first Longevity Board, chaired by Eli Lilly’s Group VP of Molecular Discovery and featuring Nobel laureate Michael Levitt. Inside the AI strategy, dual-purpose targets,…
Adrian Woolfson trained under a Nobel laureate at Cambridge, ran global oncology programs at the world’s largest pharmaceutical companies, and led research and development at Sangamo Therapeutics during the first…
Ray Kurzweil has spent two decades arguing that by 2029, medical progress will add more than a year to your remaining life expectancy for every year that passes. A Nobel-laureate…
For four decades, a single protein drove roughly a third of all human cancers, and nobody could build a drug against it. Here is why that story is finally changing,…
Five Nobel laureates are quietly orbiting Isomorphic Labs, the Alphabet-backed company trying to use artificial intelligence to end the world’s deadliest diseases. What they are building would have been science…
For decades, confirming Alzheimer’s disease required a spinal tap or a PET scan that few patients ever received. In 2025 the FDA cleared the first plasma p-tau217 blood test, and…
A landmark Science study reveals that genes control over 50 percent of lifespan variation. Meanwhile, the PROACT trial uses polygenic risk scores to find hidden heart disease, and whole genome…
A new generation of AI systems does not just assist scientists; it organizes itself into research teams, designs experiments, debates hypotheses, and identifies drug candidates at speeds no human laboratory…
A foundation model company just paid $400 million in stock for a team of fewer than 10 people. The implications for drug discovery, precision medicine, and the entire healthcare AI…
Zach RobertsSign up for personalized wellness coaching and the Daily Discovery Newsletter.